- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Anti-VEGF Drugs Not Associated With Increased Risk of AEs in Eye Diseases
Last week, an overview of systematic reviews and meta-analyses investigating systemic adverse events associated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments was published in JAMA Ophthalmology.
Last week, an overview of systematic reviews and meta-analyses investigating systemic adverse events associated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments was published in JAMA Ophthalmology. The review encompassed adverse events (AEs) in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) being treated with the intravitreal anti-VEGF agents ranibizumab and bevacizumab.
Researchers analyzed 21 systematic reviews published between January 1, 2011, and June 30, 2016. Of these, 11 analyzed serious AEs as the primary outcome, and the remaining 10 considered serious AEs secondary endpoints. The reviews were screened for quality.
This research found that the studies investigated largely agreed that anti-VEGF treatments were not associated with an increased risk of serious AEs in eye indications; 10 reviews studied patients with AMD that included 2 to 12 randomized controlled trials (RCTs) each, and overlapping comparisons were observed for 7 reviews. Six reviews studied patients with DME, and included 4 to 18 RCTs each, with overlapping comparisons found in 4 reviews. Lastly, 3 reviews analyzed serious AEs as the primary outcome and included patients with all 3 diseases.
In total, 19 serious AEs were reported in the AMD group (among 15,102 patients), 7 were reported in the DME group (among 5357 patients), and 6 were reported in the RVO group (among 1349 patients). Eight were reported in a grouped analysis of patients with AMD, DME, and RVO.
The authors noted some potential limitations of the study: reviews were only included if they reported 95% confidence intervals for serious AEs. In addition, researchers did not re-extract data from original research, which was deemed to be outside the scope of their review. Finally, the risks related to the duration of various treatments as well as AEs related to drug doses were not analyzed due to data not being reported in the included meta-analyses.
The overview of prior reviews and meta-analyses suggests that anti-VEGF treatments do not increase the risk of AEs. However, the authors advise caution in older patients with AMD who may be at a higher risk of hemorrhagic events when taking ranibizumab.
Reference
Thulliez M, Angoulvant D, Pisella PJ, et al. Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti-vascular endothelial growth factor medication use. JAMA Opthalmol. Published online March 22, 2018. doi:10.1001/jamaophthalmol.2018.0002.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
